From the publishers of JADPRO

MPN Resource Center

Advertisement

NCCN adds newly approved long-acting interferon to its practice guidelines for polycythemia vera

The National Comprehensive Cancer Network has updated its guidelines to recommend ropeginterferon alfa-2b for treatment of polycythemia vera. This update is based on the November 2021 US Food and Drug Administration approval of ropeginterferon alfa-2b.

Managed Healthcare Executive
Advertisement
News & Literature Highlights
Advertisement
Advertisement